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furthermore prolonged the latency to epithelial ulceration 
and reduced ulcer duration. Proliferation measurements with 
BrdU did not show any substantial effects of DS. The 
adherens junction protein β-catenin did significantly increase 
during irradiation, which occurred earlier with additional DS 
treatment. The hypoxia markers HIF-1α and GLUT-1 showed a 
progressive increase during irradiaton alone, which, however, 
was also not influenced by DS. IL-1β and NF-κB as markers of 
inflammation were dramatically increased during irradiation. 
While DS treatment abolished the radiation-induced increase 
of IL-1β, however, no systematical effect on the expression 
of NF-κB was observed.  
 
Conclusion: DS has a significant mucoprotective effect. This 
is not based on stimulation of epithelial proliferation nor on 
modulation of radiation-induced hypoxic changes. In 
contrast, reduced or modulated inflammatory processes 
and/or increased/modified function of adherens junctions 
may have a mechanistic role. This hypothesis, however, 
needs to be validated in further studies. 
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Purpose or Objective: Anticancer treatment affects 
composition and concentrations of metabolites in body fluids. 
In case of head and neck (HNC) cancers the acute radiation 
syndrome (ARS) was studied only at the genomic, proteomic 
and lipidomic levels. We aimed to identify and investigate 
molecular processes of treatment toxicity in HNC patients 
using high resolution NMR and NMR-based metabolomics. 
 
Material and Methods: Forty five patients with HNC were 
treated with radiotherapy (RT) or cisplatin-based 
chemoradiotherapy (CHRT). Blood samples were collected 
within a week after RT/CHRT completion. The ARS was 
evaluated using Multi-parameter Monitoring (MPM) – an 
original evaluation system designed by the study 
investigators. The patients were divided into two classes (of 
high and low ARS) on the basis of the highest individual ARS 
value observed during the treatment. The NMR spectra of the 
serum samples were acquired on 400.13 MHz Bruker 
spectrometer at 310 K. The referenced to alanine and 
bucketed to 0.002 ppm spectra were analyzed using principal 
component analysis (PCA) and orthogonal partial least 
squares discriminant analysis (OPLS-DA). Additional statistical 
analyses (Mann-Whittney test, Pearson correlation) were 
performed on quantified metabolites. 
 
Results: In the high ARS group we observed the increased 
signals of N-acetyl-glycoprotein – the NMR marker of 
inflammation, and acetate – a product of beta-oxidation of 
adipose tissue fatty acids. The high ARS group showed also 
the decreased signals of metabolites involved in energy 
metabolism: branched chain amino acids (BCAAs), alanine, 
creatinine, carnitine and glucose as well as decreased choline 
containing compounds reflecting disturbed membrane 
metabolism. Furthermore, we observed the positive 
correlations between C-reactive protein (CRP) and N-acetyl-
glycoprotein as well as acetate and a percentage weight loss 
during the treatment. CRP was also negatively correlated 
with alanine and BCAAs. 
 
Conclusion: 1H NMR is an efficient tool for detection of 
RT/CHRT toxicity markers in human serum. The results 
indicate at least three concomitant processes related to high 
treatment toxicity (high ARS): inflammation, altered energy 
metabolism and disturbed membrane metabolism. The 
combination of clinical and molecular approaches could 
deliver comprehensive information on treatment response, 
allowing monitoring and/or prediction of tolerance/toxicity 
of therapy as well as its outcome. Such approach gives a step 
forward into personalized therapy. 
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Purpose or Objective: Cytokines, which are involved in 
chronic inflammation, are also related to tumor 
aggressiveness and resistance to treatment in many cancers. 
However, there are limited reports on the significance of 
cytokines in tumor response to radiotherapy (RT). The aim of 
this study was to analyze serum cytokine levels and identify 
their association with treatment outcome in patients with 
hepatocellular carcinoma (HCC) treated with RT. 
 
Material and Methods: Patients with HCC who treated with 
RT were eligible for this prospective study. Blood samples 
were collected before and after completion of the whole RT 
course. Serum cytokine levels measured using Cytokine Bead 
Array kits were analyzed with respect to patients’ clinical 
profiles and treatment responses. 
 
Results: Between September 2008 and October 2009, 51 
patients were included in the analysis. Median follow-up 
duration was 12.3 months (range, 0.5-62.3). Forty-seven 
patients were diagnosed with modified UICC stage III or IV 
disease at the time of RT. Baseline serum IL-8 level increased 
with increasing stage and the IL-6 level was highest in 
patients with a history of pre-RT treatment (treatment-non-
naïve). A higher baseline serum IL-6 level was also observed 
in patients with treatment failure, including overall, infield, 
and outfield failure, than in those without treatment failure. 
In subgroup analysis, a significant difference in serum IL-6 
level was observed only in treatment-non-naïve versus 
treatment-naïve patients. Median overall survival and 
progression-free survival (PFS) were 13.9 and 7.7 months, 
respectively. Elevated serum IL-6 level was significantly 
associated with PFS for patients with infield failure (HR 
1.011, p<0.0001). 
 
Conclusion: The current findings suggest that assessment of 
baseline serum IL-6 level may be helpful to predict treatment 
outcome after RT for HCC, especially in patients who undergo 
treatment before RT. 
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Purpose or Objective: Neoadjuvant radiotherapy (NeoRT) 
improves tumor local control and tumor resection in many 
cancers. The timing between the end of the NeoRT and 
surgery is driven by the occurrence of side effects or the 
tumor downsizing. Some studies demonstrated that the 
